ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising th ...

GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) ...

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: Listening to Patients w ...

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City. PolyPid's fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, will take place ...

Core Insights - Cellectar Biosciences, Inc. announced the acceptance of an abstract for a poster presentation at the AACR Special Conference on Pancreatic Cancer Research, highlighting preclinical data for CLR 121225, an actinium-based radio conjugate for treating hypoxic pancreatic ductal adenocarcinoma [1][2] Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform to enhance efficacy and safety [3][4] Product Pipeline - The company's product pipeline includes lead assets such as iopofosine I 131, CLR 121225, and CLR 121125, targeting various solid tumors with significant unmet needs, including pancreatic cancer and triple-negative breast cancer [4][5] Clinical Trials and Designations - Iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma and CNS lymphoma, and is eligible for a Pediatric Review Voucher from the FDA upon approval, having received multiple designations for various cancer indications [5]

Company Overview - NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [4] - The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [4] - NRx Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100, applying for the Commissioner's National Priority Voucher Program for suicidal depression treatment [4] HOPE Therapeutics - HOPE Therapeutics, Inc. is a subsidiary of NRx Pharmaceuticals, aiming to establish a network of interventional psychiatry clinics offering ketamine, transcranial magnetic stimulation (TMS), and other therapies for patients with suicidal depression [5] - The company plans to integrate a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [5] Upcoming Events - Jonathan Javitt, M.D., M.P.H., Chairman and CEO of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025, from 4:30 to 5:00 PM ET [1] - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [2] - Management will also engage in one-on-one investor meetings during the conference, with interested investors encouraged to contact their H.C. Wainwright representative or Brian Korb at astr Partners [3]

Core Insights - Kura Oncology, Inc. is hosting two virtual investor and analyst events to showcase its farnesyl transferase inhibitor (FTI) program, emphasizing its leadership in targeting cancer signaling pathways for solid tumors and hematologic malignancies [1][5] Event Summaries - The first event on September 16, 2025, will focus on the preclinical program of FTIs, discussing their synergistic combinations with targeted therapies such as tyrosine kinase inhibitors, RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors [2] - The second event on October 18, 2025, will present clinical data from the 2025 ESMO Congress, including the first clinical insights from KO-2806, Kura's next-generation FTI, which aims to address resistance mechanisms in cancer [3] ESMO Congress Presentations - Kura will present preliminary results from the FIT-001 phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma on October 18, 2025 [4] - A phase 1 study of KO-2806 as monotherapy in advanced solid tumors will be presented on October 19, 2025 [4] - Results from the KURRENT-HN trial involving tipifarnib and alpelisib in recurrent/metastatic head and neck squamous cell carcinoma will be shared on October 20, 2025 [4] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer, with a pipeline targeting cancer signaling pathways and addressing high-need hematologic malignancies and solid tumors [5] - The company is developing ziftomenib, a menin inhibitor for acute myeloid leukemias, and is advancing both menin and farnesyl transferase inhibition strategies to tackle resistance mechanisms in solid tumors [5][6]

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines – IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder can ...

SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has completed the termination of the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas, and the holders and beneficial owners of American Depositary Shares evidenced by American ...

CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, Sept. 8, 2025 at 7:45 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDG ...